Erste Asset Management GmbH Buys New Holdings in Immunome, Inc. $IMNM

Erste Asset Management GmbH bought a new stake in Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 52,000 shares of the company’s stock, valued at approximately $1,123,000.

A number of other large investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Immunome by 8.3% in the fourth quarter. TD Asset Management Inc now owns 759,192 shares of the company’s stock valued at $16,307,000 after purchasing an additional 57,912 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Immunome by 19.0% in the fourth quarter. Intech Investment Management LLC now owns 27,015 shares of the company’s stock valued at $580,000 after purchasing an additional 4,311 shares in the last quarter. Geode Capital Management LLC raised its stake in Immunome by 24.6% during the fourth quarter. Geode Capital Management LLC now owns 2,361,381 shares of the company’s stock worth $50,731,000 after acquiring an additional 466,806 shares in the last quarter. Finally, PSP Research LLC acquired a new position in Immunome during the fourth quarter worth $542,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Max Rosett sold 65,000 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares in the company, valued at approximately $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the stock in a transaction dated Friday, June 5th. The stock was acquired at an average price of $19.45 per share, with a total value of $204,225.00. Following the completion of the purchase, the director owned 43,415 shares of the company’s stock, valued at $844,421.75. This represents a 31.90% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have sold 139,438 shares of company stock valued at $2,964,664. 7.21% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IMNM has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Leerink Partners dropped their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Truist Financial increased their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Finally, Stephens dropped their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $18.16 on Thursday. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65. The firm has a market cap of $2.06 billion, a PE ratio of -7.63 and a beta of 2.04. The business has a fifty day moving average of $21.92 and a 200-day moving average of $21.71.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.